New Zealand markets closed

Catalent, Inc. (CTLT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
132.73+0.42 (+0.32%)
At close: 4:03PM EDT
132.73 0.00 (0.00%)
After hours: 04:20PM EDT

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
http://www.catalent.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees17,300

Key executives

NameTitlePayExercisedYear born
Mr. John R. ChiminskiChairman & CEO3.17M22.37M1964
Mr. Alessandro MaselliPres & COO3.78MN/A1972
Mr. Thomas P. CastellanoSr. VP & CFO731.92k483.08k1980
Mr. Steven L. FasmanSr. VP, Gen. Counsel & Corp. Sec.1.32M2.43M1963
Ms. Karen A. FlynnPres of Biologics & Chief Commercial Officer1.15MN/A1963
Mr. Ricky HopsonVP & Chief Accounting OfficerN/AN/A1976
Mr. Julien MeissonnierVP & Chief Scientific OfficerN/AN/AN/A
Mr. Paul SurdezVP of Investor RelationsN/AN/AN/A
Mr. Michael J. GrippoSr. VP of Strategy & Corp. Devel.N/AN/A1969
Mr. Ricardo PravdaSr. VP & Chief HR OfficerN/AN/A1972
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Corporate governance

Catalent, Inc.’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 10; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.